- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | Nuvectis Pharma Q2 Loss Widens From Higher Costs, Shares Down | 2 | RTTNews | ||
| 04.08. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 04.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 04.08. | Nuvectis Pharma, Inc.: Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights | 409 | GlobeNewswire (Europe) | Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group ("Haisco"), transforming the company into a late-stage clinical... ► Artikel lesen | |
| 23.07. | China approves Nuvectis' ciprocopan for blood disorder PNH | 1 | Investing.com | ||
| 23.07. | China erteilt Zulassung für Nuvectis-Medikament Ciprocopan zur Behandlung der Blutkrankheit PNH | 1 | Investing.com Deutsch | ||
| 23.07. | Nuvectis Pharma, Inc.: Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors | 288 | GlobeNewswire (Europe) | First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program... ► Artikel lesen | |
| 14.07. | Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data | 799 | Newsfile | New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco... ► Artikel lesen | |
| 08.07. | Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? | 2 | Zacks | ||
| 30.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kapitalerhöhung mit hohem Abschlag: Nuvectis Pharma Aktie bricht um 25 % ein | 3 | Investing.com Deutsch | ||
| 30.06. | Nuvectis Pharma shares slide 19% on pricing of $100M stock offering | 1 | Seeking Alpha | ||
| 30.06. | Nuvectis Pharma prices $100 million public offering at $20/share | 3 | Investing.com | ||
| 30.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 29.06. | Nuvectis Pharma announces public share offering to support drug programs | 1 | Seeking Alpha | ||
| 29.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 26.06. | What Makes Nuvectis Pharma (NVCT) a New Buy Stock | 1 | Zacks | ||
| 24.06. | Haisco and Nuvectis sign licensing deal for two drugs | 3 | Pharmaceutical Technology | ||
| 23.06. | Haisco lizenziert Wirkstoffkandidaten an Nuvectis - 40 Millionen US-Dollar Sofortzahlung | 14 | Investing.com Deutsch |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Breaking News! NurExone Biologic plant großes Börsen-Upgrade! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,660 | +1,20 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,340 | 0,00 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen | |
| NOVOCURE | 15,365 | -0,19 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,050 | +0,56 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 2,050 | +0,99 % | Oxford Nanopore Tech - Appointment of CDPO | ||
| ROCKET PHARMACEUTICALS | 3,400 | +2,10 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| PALISADE BIO | 2,000 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development | Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,858 | +0,14 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer | FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,552 | -1,69 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA | Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans... ► Artikel lesen | |
| PERSONALIS | 14,605 | -0,92 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? |
Das Unternehmen NUVECTIS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 23,610 Euro und damit -0,51 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.